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Introduction
Angiogenesis is required for tumor growth, invasion and metastatic dissemination, hence the strong rationale for an antiangiogenic therapy. Numerous angiogenesis-targeting agents have been admitted to the ranks of cancer therapeutics (1); most of them are used in polytherapy regimens (2) .
The most validated antiangiogenic strategy targets the vascular endothelial growth factor (VEGF) axis. VEGF can be blocked directly, as with the antibody bevacizumab (Avastin®), or indirectly by inhibiting the receptor activity with small molecules such as multiple tyrosine kinase receptor inhibitors (RTKI). Among these, sunitinib (Sutent®), sorafenib (Nexavar®) and pazopanib (Votrient®) have been approved by the U.S. Food and Drug Administration for a number of malignancies (3) . The approval of inhibitors of angiogenesis has been limited because, after an initial prolongation of progression-free survival (PFS) and improved patient response rates, they do not always translated into better overall survival (OS), thus casting doubt on the overall efficacy of antiangiogenic therapy (4) (5) (6) . Resistance to antiangiogenic therapy has also been reported, both in preclinical and clinical studies, often associated with the activation of alternative proangiogenic pathways (7, 8) .
The progression of a growing tumor to distant metastases involves a number of steps. There is the loss of cell-to-cell adhesion, increased motility/invasion, intravasation in the bloodstream, extravasation, homing in a different site. All require permissive angiogenesis, which is also vital for the survival and proliferation of micrometastases (9) (10) (11) (12) . The majority of preclinical studies have focused on the effect of antiangiogenic therapy on primary tumor growth, with less attention to metastasis. The results are poor and controversial. In some studies, antiangiogenic therapy was extremely effective on the primary tumor and metastasis, improving survival (13) (14) (15) . However, surprisingly, recent studies reported that treatment of tumor-bearing mice, mainly with anti-VEGF/VEGFR related compounds, increased tumor invasiveness and metastasis (16) (17) (18) (19) (20) (21) (22) . Clinical 4 Unlike bevacizumab, the RTKI shave antitumor activity in monotherapy, but there appears to be no survival benefit from the combination with conventional chemotherapy (27) .
In this study we hypothesized that chemotherapy combined with angiogenesis inhibitors might influence tumor dissemination and metastasis. We therefore investigated the effect of the RTKI, sunitinib, alone or with chemotherapy on relevant murine metastatic tumor models. While sunitinib alone, in the neo-adjuvant setting, increased metastasis, the cytotoxic chemotherapy combination counteracted this unwanted tumor dissemination and overcame the resistance to angiogenesis inhibitors. 
Tumor lines
The renal adenocarcinoma cell line Renca was purchased from American Type Culture Collection (ATCC) and used within 6 months after receipt; the Renca-Luc variant was obtained by infecting Renca cells with lentiviral vector carrying the coding sequence of synthetic firefly luciferase gene, luc2 (Photinus pyralis) (22) . Tumor cells were maintained in RPMI 1640 (Voden Medical Instrument), supplemented with 10% FCS, 0.1 mM NEAA, 1 mM sodium pyruvate and 2 mM Lglutamine (Lonza Sales). Stocks of the cell line were stored frozen in liquid nitrogen, and kept in culture for no more than 3-4 weeks before injection in mice.
The Lewis Lung carcinoma cell line (LLC), obtained from DTP, DCTD Tumor Repository (www.dtp.nci.nih.gov), was used within 6 months after receipt, stocked frozen as in vivo-derived tumor fragments and maintained subcutaneously in C57/BL6 mice for no more than two generations before testing.
Renca-luc metastatic tumor model
For spontaneous metastasis studies Renca-luc cell suspensions were inoculated orthotopically (5x10 5 ) into the right renal capsule of BALB/c mice, as previously described (29) , and the primary tumor was surgically removed (nephrectomy) or not. Artificial metastases were obtained by injecting Renca-luc cells (1x10 5 ) into the tail vein (30).
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Metastasis in the lung were evaluated at the end of treatment (day 19, interim), or when primary tumor reached the same size (PC = 2x10 5 , approx. 1g).
For survival studies, mice were constantly monitored and killed at the first signs of discomfort (the day of death being considered the limit of survival). Results are plotted as the percentage survival against days after tumor transplant. The increment of lifespan (ILS) was calculated as [(median survival day of treated group − median survival day of control group) / median survival day of
control group] x 100.
Lewis lung metastatic tumor model
Tumor cells (5x10 4 ) from enzymatically digested subcutaneous tumors were injected into the right tibial muscle of C57/BL6, as described (30 Animals were euthanized at specific points after treatment started (same day, interim), or when mean primary tumor volume was ≤2000 mm 3 (different days, terminal). Primary tumors were fixed in formalin and embedded in paraffin (FFPE), or frozen on liquid nitrogen, for further analysis.
Lungs were excised and fixed in Buin's solution (Bio-Optica) and superficial metastatic nodules were counted and measured using a dissecting microscope, as described in the Supplementary methods (31) .
Histopathological examination
Primary tumors and lungs from euthanized mice were FFPE for histological analysis. Micrometastases in the lung were evaluated by hematoxylin-eosin, as specified in the Supplementary methods. Microvessel density and maturation in the primary tumor (CD31 and CD31/α-SMA double staining), and intra-tumor hypoxia were evaluated by immunohistochemistry as described in the Supplementary methods.
Western blotting
For immunoblotting, total proteins were extracted from frozen tumor samples. Blots were probed with goat anti HIF-1α antibody, 1:300 (R&D System) or mouse anti β-tubulin antibody (1:1000, Sigma Aldrich). See Supplementary methods for details.
Statistical analyses
Statistical analyses were done using Prism Software (GraphPad Prism 6 Software). Differences in tumor growth were evaluated by two-way ANOVA followed by Bonferroni's post-test. Differences in survival were analyzed by the log-rank test. The unpaired student's t-test or the non-parametric Mann-Whitney test was used to compare two groups. For more than two groups, one-way ANOVA followed by Bonferroni's post-test or the nonparametric Kruskal-Wallis test followed by Dunn's post test was used. P <0.05 was considered significant. Figure 1) . These findings indicate that sunitinib-due increase in metastases is not dependent on the effect on the primary tumor. To determine whether the sunitinib-related increase also affected established metastases, in a second experiment the primary tumor was surgically removed before treatment (i.e. adjuvant setting), ( Figure 1C ). Two days after removal of the primary tumor sunitinib treatment started and metastasis progression was followed. As shown in Figure 1C , left, sunitinib did not influence metastasis progression, and improved overall survival, though not significantly (ILS 50%, Fig.1C , right).
To confirm that sunitinib had no adverse effect on implanted metastases, mice were injected i.v.
with Renca-luc cells and sunitinib treatment started as soon as lung micro-metastases were detectable by BLI ( Figure 1D , left and middle). Sunitinib significantly reduced metastatic growth in the lung, with consequent prolongation of survival (ILS 19%, Figure 1D , right). At death all mice presented a similar metastatic burden (number of nodules >300, not shown). Pre-treatment with sunitinib for one week before i.v. injection of Renca-luc cells did not affect metastatic growth in the lung or survival (data not shown) .
The increase in metastases due to sunitinib depends on tumor stage
We used the murine Lewis Lung carcinoma (LLC) model, which spontaneously metastasizes to the lung, to confirm the above findings and to study the effects of sunitinib on metastasis formation at different tumor stages. Mice bearing LLC were treated with sunitinib, starting when tumors were palpable ( Figure 2A ), but no metastasis to the lung was detectable by histology ( These findings show for both models, that sunitinib augments metastasis in neoadjuvant-like setting and has no adverse effect on established metastases, suggesting that the increase in metastasis is related to the presence of the primary tumor, and this set the basis for our further experiments.
The combination with chemotherapy curbed the increase in metastasis driven by sunitinib
Angiogenesis inhibitors are generally used in combination with chemotherapy, which ultimately might limit or mask the negative effect of these drugs on metastasis formation.
We investigated this possibility in experiments combining sunitinib and chemotherapy drugs with different mechanisms of action and efficacy on the LLC model: paclitaxel (PTX), cisplatin (DDP), doxorubicin (Doxo), gemcitabine (Gem) and topotecan (TPT). The antitumor and anti-metastatic activities of these treatments are summarized in Figure 3 and detailed in Supplementary Table 1. Sunitinib caused a significant increase in metastases to the lung, with a modest effect on the growth of the primary tumor. These effects followed three patterns: 1) Drugs (i.e. paclitaxel and cisplatin) which as single agents only minimally affected metastasis and primary tumor growth (T/C 76% and 83%), in combination with sunitinib moderately improved antitumor activity but did not counteract the augmentation of metastasis by sunitinib ( Figure 3A, D) . 2) Doxorubicin, modestly active on primary tumor growth (T/C 53%), was significantly active on metastasis formation; in combination with sunitinib its antitumor activity increased and it prevented the sunitinib-driven metastasis augmentation ( Figure 3B, D) . 3) Drugs like gemcitabine and topotecan, which are highly active on the primary tumor (T/C 5% and 18%) and on metastasis as single agents, when combined with sunitinib did not further increase the antitumor activity, but counteracted the augmentation of metastasis ( Figure 3C, D) . 
Metronomic low doses of topotecan counteracted the metastatic spread elicited by sunitinib, acting on tumor hypoxia
The findings set out above illustrate the possibility, reported in several studies, that under certain experimental conditions, angiogenesis inhibitors can promote a metastatic phenotype, partly by creating an increasingly hypoxic tumor microenvironment. We investigated the effect on metastasis formation of sunitinib with topotecan administered daily at suboptimal doses, previously reported to affect the hypoxic tumor microenvironment (34, 35) .
The combination of TPT at the metronomic dose of 1 mg/kg (TPT 1) with sunitinib gave significantly better antitumor activity than the single agents alone (T/C 65%, 32%, 3% for sunitinib, TPT 1 and Sun+TPT 1) and reduced the number of metastases, even below those of untreated mice (Fig 5, A-C and Supplementary Table 2 ). The decrease in metastases was observed at the terminal analysis, therefore at a later time, due to the slowing of the primary tumor growth, once again suggesting that the effect on metastasis is independent from the size of the primary tumor and persisted after treatment suspension. Interestingly, TPT at the metronomic dose of 0.2 mg/kg (TPT 0.2), had almost no effect on tumor growth ( Figure 5B ), but combined with sunitinib it reduced metastases too, and significantly counteracted their increase due to sunitinib ( Figure 5C and Supplementary Table 2 ).
To examine the mechanism by which topotecan contrasted sunitinib-induced metastatic spread, we analyzed intra-tumor hypoxia by pimonidazole staining after metronomic TPT 1 treatment ( Figure   5D , top). TPT 1 alone or with sunitinib significantly reduced intra-tumor hypoxia compared to the sunitinib and vehicle groups. Thus hypoxia-induced HIF1-α protein accumulation in sunitinib- 
Discussion
The discovery of VEGF as a major regulator of endothelial cell growth and survival paved the way for translating these concepts into clinical practice, by targeting the VEGF signaling pathway as a way to block angiogenesis and inhibit tumor growth (1). However, the overall survival benefits of those antiangiogenic drugs have been modest: often the response to therapy is short-lasting, and patients become refractory or escape treatment (8, 36) . Recent preclinical studies have even shown increased invasion and metastasis in mouse tumor models treated with certain angiogenesis inhibitors (16) (17) (18) (19) (20) (21) (22) . Less clear is whether the resistance/escape to therapy using angiogenesis inhibitors, with accelerated disease progression or increased mortality, also happens in patients.
Noteworthy the preclinical studies were obtained with single-agent treatment, although most clinical trials with angiogenesis inhibitors are in patients already treated with-or added tochemotherapy, which could well be responsible for the final outcome.
In this study, first we re-examined the experimental conditions in which small-molecule RTKI (e.g. sunitinib) boost metastasis, and we found that sunitinib promoted metastasis only in a neo-adjuvant setting. We also confirmed that sunitinib can suppress metastatic growth, leading to an overall survival benefit for mice. Then, in the LLC model, we assessed whether chemotherapy could counteract the pro-invasive/pro-metastatic effects of sunitinib, and found that these effects were chemotherapy-sensitive and dose-schedule-dependent. It is known that the host response plays a role in the response/resistance to antiangiogenic therapy, but also to chemotherapy (37). Therefore we chose to work with murine tumor models that allow us to study metastatic spread in progression. This is in contrast with previous reports of increased metastasis formation after surgery of the primary tumor (16, 19) . However, those studies used sunitinib at high doses for a short period (a schedule not reflecting clinical practice), recently reported to be the only conditions in which metastasis is facilitated (19, 39) . Interestingly, while leading to an increase in metastasis, sunitinib per se inhibited the growth of the primary tumor, mirrored by increased mouse survival. Sunitinib can extend progression free survival and overall survival in metastatic renal carcinoma patients (38) . Therefore we believe that in this model and at these experimental conditions the survival gain is due to sunitinib's strong effect on the primary tumor and on established metastases, hiding the negative influence on metastasis formation. In light of the above observation, our findings might explain why an increase in metastasis have never been observed in the clinical practice and sunitinib therapy is beneficial for patients with mRCC. In fact, patients do not receive sunitinib in the neo-adjuvant setting, but it is often given later after the removal of the primary tumor (26, 38).
Contrary to previous reports in which treatment with sunitinib prior to intravenous injection of tumor cells led to a greater metastatic take (16, 19) , in our experimental conditions we did not find any conditioning effect to promote the growth of metastasis. Rather, as recently reported (39) Having set the appropriate experimental conditions, we found that an opportune combination therapy can curb sunitinib's adverse effects on spontaneous metastasis from the LLC. However, different cytotoxic drugs affected metastasis to different degrees, partially reflecting their intrinsic antitumor activity. Only the combination of sunitinib with gemcitabine or topotecan (but not paclitaxel and cisplatin) reduced the metastatic burden compared to untreated controls, and there was a strong effect on the primary tumor as well. This prompts us to hypothesize that the combination's final outcome might be due to the antitumor effect of the chemotherapy. With doxorubicin, however, there was strong abrogation of the sunitinib-augmented metastasis, but only a moderate effect on the primary tumor. Cytotoxic drugs have different activity on the primary tumor and metastatic sites and this was particularly evident for doxorubicin (40, 41 ). However it is very possible that the outcome of chemotherapy is influenced by the tumor microenvironment, such as vascular cells that can be susceptible to angiogenesis inhibitors in combination with chemotherapy (42) . Furthermore the host immune system can influence the response to chemotherapy at multiple levels and ultimately influence metastasis (31, 43) . Sunitinib is rarely used in combination with chemotherapy in clinical practice, as no clear clinical benefit has been reported combining multitargeted antiangiogenic RTKI with chemotherapy (27, 44) . The limited advantage we observed combining sunitinib with chemotherapy raises the question whether these RTKI differ for example from the anti-VEGF antibody bevacizumab in their antiangiogenic actions or in their ability to facilitate chemotherapy drug delivery and activity. Mechanism-based combination therapies aimed at impeding the "bad" consequences of antiangiogenic therapy and improving the overall therapeutic response are needed (45) .
Several mechanisms have been proposed to explain the increase in metastasis by angiogenesis inhibitors observed in preclinical studies. They relate to the acquisition of a more malignant tumor phenotype, or to changes of the tumor vasculature, or to abnormal recruitment of pro-inflammatory cells and production of cytokines (4). Hypoxia is a key mediator of tumor progression, contributing to poor patient survival (46) . After anti-VEGF-based treatment, tumor hypoxia increases, and HIF-1α is activated, so the tumor responds by adapting or evading it (46, 47) 
topotecan, at low daily doses (metronomic regimen), inhibited the accumulation of the α subunit of HIF-1 by a mechanism independent of DNA replication-mediated DNA damage (34) , then confirmed in a multi-histology target-driven pilot trial on tumor biopsies from patients receiving topotecan (48).
We found that i) metronomic topotecan counteracted the sunitinib-increased metastasis more than a standard dose; ii) even at the suboptimal dose of 0.2 mg/kg, which does not affect tumor growth, topotecan contained the increment of metastasis; iii) metronomic topotecan added to sunitinib reduced intra-tumor hypoxia and inhibited HIF-1α protein accumulation. Increased activity of bevacizumab in combination with daily low doses of topotecan was reported to be associated with inhibition of HIF-1α transcription (35); however tumor invasiveness was not evaluated in that study. Although these findings suffer from the limited specificity of topotecan as an HIF-1α targeting drug, we feel the effect of metronomic topotecan on metastasis is hypoxia-mediated rather than a consequence of a direct effect on tumor cells, because sub-otimal dose of topotecan (0.2 mg/kg) counteracted sunitib-due increase in metastases without affecting primary tumor growth.
The conclusion that in our model, hypoxia in the primary tumor is what accelerates metastases, and appropriate drugs in combination regimens can impair this, is in line with two recent reports pointed to HIF-1α as a major mediator of metastasis dissemination induced by antiangiogenic treatment (20, 21) .
Our preclinical findings indicate that the combination of RTKI with chemotherapy can influence metastasis and this might depend on the mechanism of action of the drug and its regimen. Our study used only two murine tumors and few angiogenesis inhibitors, so extrapolation to humans and other angiogenesis inhibitors calls for caution. Recently different outcomes in the promotion of metastasis have been shown, depending on the angiogenesis inhibitor, but also on the preclinical tumor model (19) .
Angiogenesis therapies targeting VEGF/VEGFR pathways are giving some benefits to cancer patients. However, the often modest effects might depend not only on the lack of response of the tumor, but also on our inability to use those drugs appropriately. Combining antiangiogenic compounds with other treatment modalities is a reasonable strategy for the best therapeutic results. 
